Condition 1: embolism, thrombosis. Condition 2: acute coronary syndrome. Arterial embolism and thrombosis Acute ischemic heart disease, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Alborz Darou enoxaparin for 3 to 5 days (40 mg every 12 hours). Intervention 2: Control group: Clexane manufactured by france for 3 to 5 days (40 mg every 12 hours)
Sponsors
Alborz Darou
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: patients with acute coronary syndrome who are indicated for therapeutic enoxaparin patients with acute venous thromboembolism who are indicated for therapeutic enoxaparin
Exclusion criteria
Exclusion criteria: previous history of bleeding disorders presence of acute bleeding taking anticoagulants renal failure with glomerular filteration <80 ml/min
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti-Xa activity in blood. Timepoint: 4 hours after second dose of enoxaparin. Method of measurement: blood sample. | — |
Secondary
| Measure | Time frame |
|---|---|
| Any adverese events will be compared between clexane and alborz darou enoxaparin. Timepoint: immediately after drug injection and during hospitalization. Method of measurement: all possible adverese events after drug injection and during hospitalization period will be recorded and compared between clexan and Alborz darou enoxaparin. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarzad Masoudkabir
Tehran University of Medical Sciences
Outcome results
None listed